U.S. biotech Vertex Pharmaceuticals has extended its drug discovery partnership with Oxford-based Genomics Limited by an additional four years in a deal the U.K. company says could exceed…

U.S. biotech Vertex Pharmaceuticals has extended its drug discovery partnership with Oxford-based Genomics Limited by an additional four years in a deal the U.K. company says could exceed $220 million (€200 million). The post Oxford-based Genomics keeps Vertex on board for another four years, potential $220M deal appeared first on European Biotechnology Magazine.

Source disclosure

This is a source-linked briefing. Read the original report from European Biotechnology Magazine .